GCP REFERENCES

TABLE OF CONTENTS

FDA Code of Federal Regulations - Title 21 Food and Drugs (CFR 21)
  - Part 11 - Electronic Records; Electronic Signatures
    - Guidance for Industry - Part 11, Electronic Records; Electronic Signatures
  - Part 50 - Protection of Human Subjects
  - Part 54 - Financial Disclosure by Clinical Investigators
  - Part 56 - Institutional Review Boards
  - Part 312 - Investigational New Drug Application
  - Part 314 - Applications for FDA Approval to Market a New Drug
  - Part 320 - Bioavailability and Bioequivalence Requirements

Preambles to GCP Regulations
Parts 50 and 56
  - Protection of Human Subjects; Informed Consent (January 27, 1981)
  - Protection of Human Research Subjects; Clinical Investigations Which May Be Reviewed Through Expedited Review Procedure Set Forth in FDA Regulations (January 27, 1981)
  - Federal Policy for the Protection of Human Subjects (June 18, 1991)
  - Protection of Human Subjects; Informed Consent; Proposed Rule (September 21, 1995)
  - Protection of Human Subjects; Informed Consent, Part II (October 2, 1996) [html]
  - Protection of Human Subjects; Informed Consent and Waiver of Informed Consent Requirements in Certain Emergency Research; Final Rules (October 2, 1996) [text]
  - Protection of Human Subjects; Informed Consent (December 22, 1995)
  - Protection of Human Subjects; Informed Consent Verification; Final Rule (November 5, 1996)
  - Additional protections for children (66 FR 20589-600, April 24, 2001)

Part 54
  - Financial Disclosure by Clinical Investigators; Final Rule (December 31, 1998)
  - Financial disclosures by a Clinical Investigator (63 FR 72171-81, December 31, 1998)

Parts 312 and 314
  - Proposed New Drug, Antibiotic, and Biologic Drug Product Regulations (June 9, 1983)
  - New Drug and Antibiotic Regulations (February 22, 1985)
  - New Drug, Antibiotic, and Biologic Drug Product Regulations (March 19, 1987)
Investigational New Drug Applications and New Drug Applications (September 8, 1995)
Investigational New Drug Applications and New Drug Applications (February 11, 1998)
Disqualification of a Clinical Investigator (February 16, 1996)
Disqualification of a Clinical Investigator (September 5, 1997)
 Expedited Safety Reporting Requirements for Human Drug and Biological Products (October 7, 1997)
Clinical Hold for products intended for life threatening conditions (65 FR 34963-71, June 1, 2000)

Part 320
Retention of BE and BA testing samples (April 28, 1993)

Guidances and Information Sheets on Good Clinical Practice in FDA-Regulated Clinical Trials

FDA Information Sheets for Institutional Review Boards and Clinical Investigators
  General
    Frequently Asked Questions
    Cooperative Research
    Non-local IRB Review
    Continuing Review After Study Approval
    Sponsor - Investigator - IRB Interrelationship; Foreign Clinical Studies, Acceptance of (Revised March 16, 2001); Charging for Investigational Products; Recruiting Study Subjects; Payment to Research Subjects; Screening Tests Prior to Study Enrollment
    Informed Consent, A Guide To
    Use of Investigational Products When Subjects Enter a Second Institution
    Coverage of Personal Importations (updated 12/14/2001)
    Exception from Informed Consent for Studies Conducted in Emergency Settings: Regulatory Language and Excerpts from Preamble
    "Off-Label" and Investigational Use of Marketed Drugs, Biologics and Medical Devices
  Drugs and Biologics
  Medical Devices
  FDA Operations
  Appendices
    Appendix A: A List of Selected FDA Regulations
    Appendix B: 21 CFR PART 50
    Appendix C: 21 CFR PART 56
    Appendix E: Significant Differences in FDA and HHS Regulations
    Appendix F: The Belmont Report
    Appendix G: Declaration of Helsinki: 1989 version
    Appendix H: A Self-evaluation Checklist for IRBs
Appendix I: FDA District Offices
Appendix J: Important FDA Contacts for Clinical Trials
Appendix K: Web Sites of Interest for Good Clinical Practice and Clinical Trial Information

- ICH E6 - Good Clinical Practice: Consolidated Guideline
- ICH E3 - Guideline for Industry Structure and Content of Clinical Study Programs
- ICH E5 - Ethnic Factors in the Acceptability of Foreign Clinical Data
- ICH E10 - Choice of Control Group and Related Issues in Clinical Trials
- Guidance for Industry and Clinical Investigators on the Use of Clinical Holds Following Clinical Investigator Misconduct
- Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection
- Guidance for Industry: IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations
- Guidance for Industry: Guideline for the Monitoring of Clinical Investigators
- Guidance for Industry: Acceptance of Foreign Clinical Studies
- Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions
- Guidance for Industry: Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs
- Computerized Systems Used in Clinical Trials
- Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies
- Guidance for Industry: Financial Disclosure by Clinical Investigators
- Guidance for Industry on Handling and Retention of Bioavailability and Bioequivalence Testing Samples: Availability

Bioresearch Monitoring Program
- CPGM for Clinical Investigators
- CPGM for Sponsors, Monitors, and Contract Research Organizations
- CPGM for Good Laboratory Practice (Non-Clinical Laboratories)
- CPGM for In-Vivo Bioequivalence Compliance Program 7348.001
- CPGM for Institutional Review Boards

OCR/HIPAA Privacy/Security/Enforcement Regulation

Directives of the European Parliament